Mga Batayang Estadistika
| LEI | 549300JM7MIET5QG2X15 |
| CIK | 1478069 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ContraFect Corp
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2024 |
US2123264093 / CONTRAFECT CORP / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36577 Cont |
|
| November 8, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| November 3, 2023 |
CONTRAFECT CORPORATION 7,034,883 Shares Common Stock Offered by the Selling Securityholder Table of Contents Filed pursuant to Rule 424B3 Registration No. 333-275148 PROSPECTUS CONTRAFECT CORPORATION 7,034,883 Shares Common Stock Offered by the Selling Securityholder The selling securityholder or any of its pledgees, donees, transferees, assignees or other successors-in- interest may offer and sell up to 7,034,883 shares in the aggregate of common stock identified above, which shares ar |
|
| October 31, 2023 |
CONTRAFECT CORPORATION 28 Wells Avenue, Third Floor Yonkers, New York 10701 CONTRAFECT CORPORATION 28 Wells Avenue, Third Floor Yonkers, New York 10701 October 31, 2023 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 30, 2023 |
Power of Attorney (included on signature page) S-1 Table of Contents As filed with the Securities and Exchange Commission on October 30, 2023 Registration No. |
|
| October 30, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) CONTRAFECT CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2)(4) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Units, each consisting of one share of Common Stock, par value $0. |
|
| October 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) CONTRAFECT CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| October 24, 2023 |
As filed with the Securities and Exchange Commission on October 24, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission on October 24, 2023 Registration No. |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissi |
|
| September 25, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 18, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update YONKERS, New York – August 14, 2023 — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, an |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36577 ContraFec |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 27, 2023 |
Form of Class C Common Stock Purchase Warrant EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| June 27, 2023 |
Form of Class D Common Stock Purchase Warrant EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| June 27, 2023 |
EX-10.1 Exhibit 10.1 CONTRAFECT CORPORATION June 26, 2023 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: ContraFect Corporation, a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise all of the Class A Common Stock Purchase Warrant issued to you on December 14, 2022 (with a current exerci |
|
| June 20, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 18, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2023 |
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update YONKERS, New York – May 15, 2023 — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibi |
|
| May 15, 2023 |
Non-Employee Director Compensation Program EX-10.1 Exhibit 10.1 CONTRAFECT CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of ContraFect Corporation (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, |
|
| May 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 1, 2023 |
CONTRAFECT CORPORATION 28 Wells Avenue, Third Floor Yonkers, New York 10701 CORRESP CONTRAFECT CORPORATION 28 Wells Avenue, Third Floor Yonkers, New York 10701 May 1, 2023 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 S-3/A Table of Contents As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) CONTRAFECT CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| April 3, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36577 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 31, 2023 |
EX-99.1 Exhibit 99.1 ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update YONKERS, New York – March 31, 2023 — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of li |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| March 2, 2023 |
EX-1.1 2 d476027dex11.htm EX-1.1 Exhibit 1.1 CONFIDENTIAL February 28, 2023 Michael Messinger Chief Financial Officer ContraFect Corporation 28 Wells Ave. Yonkers, NY 10701 Dear Mr. Messinger, This agreement (the “Agreement”) constitutes the agreement between ContraFect Corporation, a Delaware corporation (the “Company”), and Maxim Group, LLC (“Maxim” or the “Lead Manager”), that Maxim shall serve |
|
| March 2, 2023 |
EX-99.1 Exhibit 99.1 ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., Feb 28, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the trea |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| March 2, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 28, 2023 between ContraFect Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| March 2, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-246359 PROSPECTUS SUPPLEMENT (To Prospectus dated August 31, 2020) 128,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,372,000 Shares of Common Stock We are offering to a certain accredited and institutional investor, 128,000 shares of our common stock and a pre-funded warrant to purchase 2,372,000 sha |
|
| March 2, 2023 |
Form of Common Stock Purchase Warrant EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 2, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CONTRAFECT CORPORATION Warrant Shares: [ ⚫ ] Issue Date and Initial Exercise Date: March 2, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| February 14, 2023 |
CFRX / ContraFect Corp / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTRAFECT CORPORATION ContraFect Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That, at a meeting of the Board of Directors of the Corporation, resolutions wer |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) CONTRAFECT CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| January 31, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| January 26, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| January 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| December 23, 2022 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2022 |
EX-99.1 Exhibit 99.1 Corporate Presentation December 2022 NASDAQ: CFRX Forward Looking Statements/Disclaimer This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “shoul |
|
| December 14, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 12, 2022 between ContraFect Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and condition |
|
| December 14, 2022 |
424B5 1 d356613d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-246359 PROSPECTUS SUPPLEMENT (To Prospectus dated August 31, 2020) 4,350,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 49,913,565 Shares of Common Stock We are offering to a certain accredited and institutional investor, 4,350,000 shares of our common stock and a pre-funded wa |
|
| December 14, 2022 |
EX-1.1 2 d362493dex11.htm EX-1.1 Exhibit 1.1 CONFIDENTIAL December 12, 2022 Dr. Roger J. Pomerantz, M.D., F.A.C.P. Chief Executive Officer ContraFect Corporation 28 Wells Ave. Yonkers, NY 10701 Dear Dr. Pomerantz, This agreement (the “Agreement”) constitutes the agreement between ContraFect Corporation, a Delaware corporation (the “Company”), and Maxim Group, LLC (“Maxim” or the “Lead Manager”), t |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| December 14, 2022 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT CONTRAFECT CORPORATION Warrant Shares: [ ? ] Issue Date and Initial Exercise Date: December 15, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| December 14, 2022 |
Form of Class B Common Stock Purchase Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 14, 2022 |
Exhibit 99.1 ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., December 13, 2022 (GLOBE NEWSWIRE) ? ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of li |
|
| December 14, 2022 |
Form of Class A Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 25, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2022 |
Exhibit 99.1 ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued execution to advance exebacase and CF-370 into new clinical studies YONKERS, New York ? November 14, 2022 ? ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin pepti |
|
| November 14, 2022 |
Exhibit 10.1 Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is treated as confidential by the Company. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 13 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (if applicable) P00004 See Block 1 |
|
| September 9, 2022 |
CFRX / ContraFect Corp / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this |
|
| August 31, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2022 |
Exhibit 10.1 Transition Agreement and Release This Transition Agreement and Release (?Agreement?) is made by and between Cara Cassino, M.D. (?Executive?) and ContraFect Corporation, a Delaware corporation (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?) as of August 14, 2022 (the ?Effective Date?). Capitalized terms used but not defined in this A |
|
| August 15, 2022 |
Exhibit 99.1 ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies YONKERS, New York ? August 15, 2022 ? ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and am |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326300 (CUSIP Number) July 15, 2 |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 23, 2022 |
EX-FILING FEES 4 d360301dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ContraFect Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee |
|
| May 23, 2022 |
ContraFect Corporation 2022 Employee Stock Purchase Plan Exhibit 99.1 CONTRAFECT CORPORATION 2022 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to qua |
|
| May 23, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ContraFect Corporation (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| May 23, 2022 |
As filed with the Securities and Exchange Commission on May 23, 2022 As filed with the Securities and Exchange Commission on May 23, 2022 Registration No. |
|
| May 23, 2022 |
As filed with the Securities and Exchange Commission on May 23, 2022 As filed with the Securities and Exchange Commission on May 23, 2022 Registration No. |
|
| May 19, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 18, 2022 |
Contrafect Molecular treatments for infectious disease Corporate presentation may 2022 NASDAQ: CFRX Exhibit 99.1 Contrafect Molecular treatments for infectious disease Corporate presentation may 2022 NASDAQ: CFRX Forward Looking Statements This presentationcontains,andourofficers andrepresentatives mayfrom time to timemake,?forward-lookingstatements?withinthe meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as ?projects,? ?may,? ?will,? ?cou |
|
| May 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 16, 2022 |
Exhibit 10.1 CONTRAFECT CORPORATION 2021 EMPLOYMENT INDUCEMENT OMNIBUS INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON SEPTEMBER 14, 2021 1. GENERAL. (a) Eligible Award Recipients. Eligible Individuals are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Non-statutory Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted S |
|
| May 16, 2022 |
EX-99.1 2 d344007dex991.htm EX-99.1 Exhibit 99.1 ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis YONKERS, New York – May 16, 2022 — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and deve |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S |
|
| March 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36577 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| March 24, 2022 |
Exhibit 99.1 ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022 YONKERS, New York ? March 24, 2022 - ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and developme |
|
| February 14, 2022 |
CFRX / ContraFect Corp / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 cfrx56.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2021 (Date of Event Which |
|
| February 14, 2022 |
CFRX / ContraFect Corp / PFIZER INC - SC 13G/A2 CONTRAFECT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326300 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 13, 2021 |
CORRESP 1 filename1.htm December 13, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Davis Re: ContraFect Corporation Registration Statement on Form S-3 Filed December 8, 2021 Registration No. 333-261543 Ladies and Gentlemen: In accordance with Rule 461 |
|
| December 8, 2021 |
As filed with the Securities and Exchange Commission on December 8, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 8, 2021 Registration No. |
|
| November 19, 2021 |
As filed with the Securities and Exchange Commission on November 19, 2021 As filed with the Securities and Exchange Commission on November 19, 2021 Registration No. |
|
| November 19, 2021 |
Exhibit 99.1 CONTRAFECT CORPORATION 2021 EMPLOYMENT INDUCEMENT OMNIBUS INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON SEPTEMBER 14, 2021 1. GENERAL. (a) Eligible Award Recipients. Eligible Individuals are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Non-statutory Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted S |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2021 |
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update EX-99.1 2 d259730dex991.htm EX-99.1 Exhibit 99.1 ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update YONKERS, New York — November 15, 2021 — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for th |
|
| November 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| August 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2021 |
Exhibit 99.1 CONTRAFECT REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company?s DLA portfolio Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase YONKERS, NY ? August 13, 2021 ? ContraFect Corporation (Nasdaq: CFRX), a late cl |
|
| May 27, 2021 |
As filed with the Securities and Exchange Commission on May 27, 2021 As filed with the Securities and Exchange Commission on May 27, 2021 Registration No. |
|
| May 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2021 |
Exhibit 99.1 ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong financial position with cash and investments of $87.2 million as of March 31, 2021 YONKERS |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326300 (CUSIP Number) April 13, |
|
| April 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| March 30, 2021 |
EX-99.1 2 d167480dex991.htm EX-99.1 Exhibit 99.1 ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research and Development Authority (BARDA) contract award provid |
|
| March 30, 2021 |
Exhibit 10.16 EMPLOYMENT AGREEMENT by and between CONTRAFECT CORPORATION and MICHAEL MESSINGER THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on November 5, 2012, by and between ContraFect Corporation, a Delaware corporation (?Employer?) and Michael Messinger, a resident of New Jersey (?Employee?). WHEREAS, Employer believes that the future services of Employee will be of substantial |
|
| March 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36577 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 30, 2021 |
Non-Employee Director Compensation Program Exhibit 10.17 CONTRAFECT CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of ContraFect Corporation (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be made, as appl |
|
| March 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| March 19, 2021 |
Exhibit 1.1 CONTRAFECT CORPORATION (a Delaware corporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT March 17, 2021 SVB Leerink LLC Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: ContraFect Corpor |
|
| March 19, 2021 |
10,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-246359 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated August 31, 2020) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock. The purchase price for each share is $5.00. Our common stock is listed on the Nasdaq Capital Market under the symbol ?CFRX.? On March 16, 2021, the last reported s |
|
| March 17, 2021 |
Subject to Completion, Dated March 17, 2021 Common Stock 424B5 1 d939697d424b5.htm 424B5 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not s |
|
| March 12, 2021 |
EX-99.1 3 d122568dex991.htm EX-99.1 Exhibit 99.1 ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim futility analysis anticipated in H2 2021 Phase 3 DISRUPT stud |
|
| March 12, 2021 |
EX-10.1 2 d122568dex101.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) u RATING PAG |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2021 |
CUSIP No: 212326300 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326300 (CUSIP Numb |
|
| February 16, 2021 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) ContraFect Corporation SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of thi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 12, 2021 |
8-K 1 d122610d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of i |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ContraFect Corporation (Name of Issuer) Common Stock, par value US$0.0001 per share (Title of Class of Securities) 212326300 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2020 |
Amended and Restated Bylaws of ContraFect Corporation, as adopted on November 10, 2020 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CONTRAFECT CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR |
|
| November 13, 2020 |
Exhibit 99.1 ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the treatment of persistent MRSA bloodstream infections in COVID-19 patients YONKERS, New York ? November 13, |
|
| November 13, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTRAFECT CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR |
|
| November 13, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTRAFECT CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR |
|
| October 20, 2020 |
CFRX / ContraFect Corporation / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326300 (CUSIP Number) May 22, 202 |
|
| October 20, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 20, 2020 with respect to the common stock, par value $0.0001 per share of ContraFect Corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule |
|
| August 27, 2020 |
CORRESP CONTRAFECT CORPORATION 28 WELLS AVENUE, THIRD FLOOR YONKERS, NY 10701 August 27, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| August 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2020 |
EX-1.2 Exhibit 1.2 ContraFect Corporation Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 14, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Maxim Group LLC 405 Lexington Avenue, 2nd Floor New York, NY 10174 Ladies and Gentlemen: ContraFect Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Ag |
|
| August 14, 2020 |
EX-99.1 Exhibit 99.1 ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering, private placement with Pfizer Inc., and CARB-X grant provide significant funding to advance lead pro |
|
| August 14, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 14, 2020 Registration No. |
|
| August 14, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2020 |
EX-4.3 Exhibit 4.3 CONTRAFECT CORPORATION INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establis |
|
| August 14, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 14, 2020 Registration No. |
|
| June 17, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Comm |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326300 (CUSIP Number) May 22, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| May 29, 2020 |
212326300 / CONTRAFECT CORP / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 212326300 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326300 (CUSIP Numbe |
|
| May 27, 2020 |
Warrant to Purchase Common Stock, dated May 27, 2020 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREM |
|
| May 27, 2020 |
EX-4.2 Exhibit 4.2 WARRANT AGREEMENT This Warrant Agreement (“Warrant Agreement”) is entered into as of May 27, 2020, by and between ContraFect Corporation, a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Warrant Agent”). WHEREAS, the Company is engaged in a public offering (the “Public Offering”) of shares of common stock of the Company, par value $0 |
|
| May 27, 2020 |
EX-1.1 Exhibit 1.1 11,797,752 Shares Warrants to Purchase 8,848,314 Shares CONTRAFECT CORPORATION Common Stock UNDERWRITING AGREEMENT May 21, 2020 MIZUHO SECURITIES USA LLC CANTOR FITZGERALD & CO. As Representatives of the Several Underwriters c/o Mizuho Securities USA LLC 320 Park Avenue, 12th Floor New York, New York 10022 c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Ladi |
|
| May 27, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2020 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 22, 2020 (the “Signing Date”), by and between ContraFect Corporation, a Delaware corporation (the “Company”), and Pfizer Inc., a Delaware corporation (the “Purchaser”). WHEREAS, the Purchaser desires to purchase, and the Company desires to sell and issue, shar |
|
| May 27, 2020 |
Global Warrant Certificate, dated May 27, 2020 EX-4.3 Exhibit 4.3 UNLESS THIS GLOBAL WARRANT CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYM |
|
| May 26, 2020 |
11,797,752 Shares of Common Stock Warrants to Purchase up to 8,848,314 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228626 PROSPECTUS SUPPLEMENT (To Prospectus dated December 13, 2018) 11,797,752 Shares of Common Stock Warrants to Purchase up to 8,848,314 Shares of Common Stock ContraFect Corporation is offering 11,797,752 shares of common stock and warrants to purchase 8,848,314 shares of common stock. The common stock and warrants w |
|
| May 21, 2020 |
Subject to Completion, Dated May 21, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228626 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sel |
|
| May 21, 2020 |
S-3MEF 1 d927788ds3mef.htm S-3MEF As filed with the Securities and Exchange Commission on May 21, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or Other Jurisdiction of Incorpor |
|
| May 15, 2020 |
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update YONKERS, NY – May 15, 2020 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-re |
|
| May 15, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commi |
|
| May 15, 2020 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2020 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commi |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 18, 2020 |
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update YONKERS, NY – March 18, 2019 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threateni |
|
| March 18, 2020 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36577 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 18, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTRAFECT CORPORATION (originally incorporated on March 5, 2008) ContraFect Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the “DGCL”), does hereby certify as follows: A. The current name of the Corporation is ContraFect Corp |
|
| March 18, 2020 |
Description of ContraFect Corporation Securities EX-4.12 Exhibit 4.12 DESCRIPTION OF CONTRAFECT CORPORATION SECURITIES The following description of the capital stock of ContraFect Corporation (the “Company,” “we,” “us,” and “our”) and certain provisions of our amended and restated certificate of incorporation, as amended (our “certificate of incorporation”), and amended and restated bylaws (our “bylaws”) are summaries and are qualified in their |
|
| March 18, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Com |
|
| February 24, 2020 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) ( |
|
| February 24, 2020 |
EX-99.1 Exhibit 99.1 ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis YONKERS, New York — February 24, 2020 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic age |
|
| February 21, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) ( |
|
| February 14, 2020 |
CFRX / ContraFect Corporation / FEINBERG LARRY N - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2* (EXIT FILING) Under the Securities Exchange Act of 1934 CONTRAFECT CORPORATION. (Name of Issuer) Common Stock (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2020 |
CFRX / ContraFect Corporation / Baker Brothers Advisors LP - SCHEDULE 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 11, 2020 |
CFRX / ContraFect Corporation / Fosun Industrial Co., Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm207082d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ContraFect Corporation (Name of Issuer) Common Stock, par value US$0.0001 per share (Title of Class of Securities) 212326300 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) |
|
| February 4, 2020 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTRAFECT CORPORATION ContraFect Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That, at a meeting of the Board of Directors of the Corporation, resolutions wer |
|
| February 4, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (C |
|
| January 10, 2020 |
CFRX / ContraFect Corporation / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of thi |
|
| January 6, 2020 |
CRFX / CONTRAFECT Corp DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| December 27, 2019 |
CRFX / CONTRAFECT Corp PRE 14A - - PRE 14A PRE 14A 1 d856397dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ P |
|
| December 19, 2019 |
EX-1.1 Exhibit 1.1 25,650,000 SHARES OF COMMON STOCK OF CONTRAFECT CORPORATION UNDERWRITING AGREEMENT December 17, 2019 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Floor New York, New York 10174 Ladies and Gentlemen: The undersigned, ContraFect Corporation, a company incorpora |
|
| December 19, 2019 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) ( |
|
| December 18, 2019 |
25,650,000 Shares Common Stock $0.39 per share Final Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| December 16, 2019 |
CFRX / ContraFect Corporation / PFIZER INC - SC 13G CONTRAFECT CORPORATION Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326102 (CUSIP Number) December 12, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 12, 2019 |
EX-1.1 Exhibit 1.1 37,150,000 SHARES OF COMMON STOCK OF CONTRAFECT CORPORATION UNDERWRITING AGREEMENT December 10, 2019 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Floor New York, New York 10174 Ladies and Gentlemen: The undersigned, ContraFect Corporation, a company incorpora |
|
| December 12, 2019 |
EX-10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 9, 2019 (the “Signing Date”), by and between ContraFect Corporation, a Delaware corporation (the “Company”), and Pfizer Inc., a Delaware corporation (the “Purchaser”). WHEREAS, the Purchaser desires to purchase, and the Company desires to sell and issue, shares of |
|
| December 12, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (C |
|
| December 11, 2019 |
37,150,000 Shares Common Stock $0.27 per share Final Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| December 10, 2019 |
FWP 1 d117906dfwp.htm FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated December 10, 2019 Relating to Preliminary Prospectus dated December 9, 2019 Registration No. 333-228626 ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer YONKERS, N.Y., December 10, 2019 — ContraFect Co |
|
| December 9, 2019 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (C |
|
| December 9, 2019 |
EX-99.1 Exhibit 99.1 ContraFect Pipeline Program Pathogen Discovery Preclinical Phase 1 Phase 2 Phase 3 Bacteremia, including endocarditis Exebacase Staphylococcus aureus Prosthetic joint infections (PJI) CF-296 Staphylococcus aureus Osteomyelitis and PJI GN lysin Pseudomonas aeruginosa Broad spectrum; Gram- Amurins negative ESKAPE pathogens Klebsiella pneumoniae GN lysins Escherichia coli Enterob |
|
| December 9, 2019 |
FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated December 9, 2019 Relating to Preliminary Prospectus dated December 9, 2019 Registration No. |
|
| December 9, 2019 |
Subject to Completion, Dated December 9, 2019 Preliminary Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 12, 2019 |
ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update YONKERS, NY – November 12, 2019 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiot |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2019 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 2, 2019 |
EX-99.1 ContraFect October 2019 Differentiated, first-in-class direct lytic agents (DLAs) for life-threatening, drug-resistant infections Exhibit 99.1 This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects |
|
| October 2, 2019 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Co |
|
| August 22, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2019 |
ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update YONKERS, NY – August 9, 2019 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as a new modality for the treatment of life-threatening, antibiotic-resista |
|
| August 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2019 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 29, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commi |
|
| May 13, 2019 |
CRFX / CONTRAFECT Corp S-8 FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on May 13, 2019 Registration No. |
|
| May 10, 2019 |
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update YONKERS, NY – May 10, 2019 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, comprised of lysins and amurins, a new modality in therapeutics for life-threatening, drug-resistant infectious diseases, t |
|
| May 10, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2019 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2019 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commis |
|
| April 10, 2019 |
CFRX / ContraFect Corporation / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) March 31, 2019 (Date of Event Which Requires Filing of this S |
|
| April 2, 2019 |
CRFX / CONTRAFECT Corp DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 2, 2019 |
Exhibit 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of April 2, 2019, is made by and between ContraFect Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Roger J. Pomerantz, M.D., F.A.C.P. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS A. It is |
|
| April 2, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):April 1, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 2, 2019 |
Exhibit 10.2 Exhibit 10.2 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Steven C. Gilman, Ph.D. (“Executive”) and ContraFect Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, the Parties have previously entered into that certain letter agreement regarding Executive |
|
| March 20, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Com |
|
| March 14, 2019 |
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update YONKERS, NY — March 15, 2019 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced financial |
|
| March 14, 2019 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36577 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 39-2072586 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| February 26, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) ( |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 212326102 (CUSIP Number) December 3 |
|
| February 14, 2019 |
CFRX / ContraFect Corporation / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ContraFect Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2019 |
CFRX / ContraFect Corporation / 683 Capital Management, LLC - FEBRUARY 14, 2019 Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* ContraFect Corporation (Name of Issuer) Common stock, $0.0001 par value (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event w |
|
| February 13, 2019 |
CFRX / ContraFect Corporation / Adage Capital Partners GP LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ContraFect Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2019 |
CFRX / ContraFect Corporation / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2019 |
CFRX / ContraFect Corporation / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) CONTRAFECT CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of thi |
|
| February 11, 2019 |
CFRX / ContraFect Corporation / FEINBERG LARRY N - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 CONTRAFECT CORPORATION. (Name of Issuer) Common Stock (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 22, 2019 |
CFRX / ContraFect Corporation / Fosun Industrial Co., Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ContraFect Corporation (Name of Issuer) Common Stock, par value US$0.0001 per share (Title of Class of Securities) 212326102 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 7, 2019 |
EX-99.1 ContraFect January 2019 Differentiated, first-in-class anti-infectives for life-threatening, drug-resistant infections Exhibit 99.1 This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “ |
|
| January 7, 2019 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Co |
|
| December 11, 2018 |
CORRESP December 11, 2018 VIA EDGAR TRANSMISSION Ms. Christine Westbrook Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: CONTRAFECT CORPORATION Registration Statement on Form S-3 (Registration No. 333-228626) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby reque |
|
| December 6, 2018 |
CFRX / ContraFect Corporation / Fosun Industrial Co., Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ContraFect Corporation (Name of Issuer) Common Stock, par value US$0.0001 per share (Title of Class of Securities) 212326102 (CUSIP Number) December 4, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 30, 2018 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on November 30, 2018 Registration No. |
|
| November 30, 2018 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED SHARE DIVIDENDS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND THE YEARS ENDED DECEMBER 31, 2017, 2016, 2015, 2014 AND 2013 (dollars in thousands) For the Nine Months Ended September 30, 2018 Years Ended December 31, 2017 2016 2015 2014 2013 Fixed Charges: Interest expense on indebtedness |
|
| November 30, 2018 |
EX-4.3 Exhibit 4.3 ContraFect Corporation INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Est |
|
| November 8, 2018 |
ContraFect Announces Third Quarter 2018 Financial Results EX-99.1 2 d649297dex991.htm EX-99.1 Exhibit 99.1 ContraFect Announces Third Quarter 2018 Financial Results YONKERS, NY – November 8, 2018 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter e |
|
| November 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (C |
|
| November 8, 2018 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2018 |
ContraFect Announces Second Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 ContraFect Announces Second Quarter 2018 Financial Results YONKERS, NY – August 9, 2018 — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the second quarter ended June 30, 2018. “Over th |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2018 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 31, 2018 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 5,000,000 Shares CONTRAFECT CORPORATION Common Stock PURCHASE AGREEMENT July 27, 2018 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: ContraFect Corporation, a Delaware corporation (the “Company”) proposes |
|
| July 31, 2018 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2018 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Comm |
|
| July 27, 2018 |
Piper Jaffray William Blair The date of this prospectus supplement is July 27, 2018. Final Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 26, 2018 |
Subject to Completion, dated July 26, 2018 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-217989 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sel |
|
| July 26, 2018 |
Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2018 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Comm |
|
| May 30, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 39-2072586 (State or other jurisdiction of incorporation) (Commission |
|
| May 30, 2018 |
EX-10.1 Exhibit 10.1 Amendment No. 1 to Steven C. Gilman Offer Letter This Amendment (this “Amendment”) to the letter agreement, dated July 21, 2016 (the “Offer Letter”), by and between ContraFect Corporation (the “Company”), and Steven C. Gilman, Ph.D. (“Executive”), is entered into by and between the Company and Executive effective as of May 29, 2018. WHEREAS, the Company and Executive desire to |
